Grafotas 100mg Capsule contains ciclosporin, a potent immunosuppressive agent primarily used to prevent organ transplant rejection and to treat various autoimmune disorders. Ciclosporin acts by selectively inhibiting the activity of T-lymphocytes, thereby suppressing the immune response responsible for graft rejection and autoimmune tissue damage. This medication is indicated for the prophylaxis of organ rejection in kidney, liver, and heart transplant recipients, as well as for the management of severe rheumatoid arthritis and psoriasis when conventional therapies are inadequate. Grafotas should be administered under strict medical supervision, with dosage individualized based on patient response and therapeutic drug monitoring to minimize toxicity. Common adverse effects include nephrotoxicity, hypertension, hyperlipidemia, and increased susceptibility to infections due to immunosuppression. Liver function tests, renal function, and blood pressure should be regularly monitored during treatment. Patients should avoid concomitant use of nephrotoxic drugs and grapefruit juice, which can alter ciclosporin metabolism. Grafotas 100mg Capsule is contraindicated in patients with hypersensitivity to ciclosporin or any component of the formulation. Due to its narrow therapeutic index, adherence to prescribed dosing and follow-up is essential to optimize efficacy and minimize risks associated with immunosuppressive therapy.